Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Zeiss Completes Acquisition of DORC
In a significant move for the ophthalmology sector, Carl Zeiss Meditec announced the successful acquisition of 100% shares of the Dutch Ophthalmic Research Center (DORC), a transaction that has now received all necessary regulatory approvals. This acquisition from Eurazeo SE,…
Qlaris Bio Begins Phase 2 Trials of QLS-111 for Eye Conditions
Qlaris Bio has commenced two critical Phase 2 trials in the United States for its innovative intraocular pressure (IOP)-lowering product, QLS‑111. These masked, randomized clinical trials are designed to investigate the efficacy of QLS‑111 in patients suffering from ocular hypertension…
West Point and Verséa Sign Supply Deal for Ocular Products
In a significant move for ocular health and treatment, West Point Optical Group (WPOG), the operator of 86 Pearle Vision stores, has joined forces with Verséa Ophthalmics in an exclusive partnership supply agreement. Under this new deal, Verséa Ophthalmics is…
Pantheon Vision Gets Another $1.8M for Corneal Implants
Pantheon Vision, a pioneering medical device company in the pre-clinical stage focused on developing bioengineered corneal implants, has secured an additional $1.8 million in funding. This recent financial boost is part of a second tranche from KeraLink International (KLI), following…
ViaLase Raises $40M for Glaucoma Laser Tech
ViaLase has successfully completed a Series C financing round, raising a substantial $40 million. This funding boost is set to accelerate the development, regulatory approval, and commercialization efforts of the ViaLase Laser, a pioneering medical device developed for the treatment…
Viatris Launches RYZUMVI™ 0.75% in the United States
Viatris Inc. announced the commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% in the United States. This treatment is the only FDA-approved eye drop available in the U.S. market designed to reverse pharmacologically-induced mydriasis, commonly caused by adrenergic agonists like…
GRF Releases Audiobook for the Visually Impaired
The Glaucoma Research Foundation (GRF) has recently released a 48-minute audiobook version of their comprehensive 40-page educational guide, “Understanding and Living with Glaucoma.” This project aims to extend the reach of their essential information to those affected by glaucoma, especially…
Aldeyra Eyes NDA Resubmission for DED Treatment
Aldeyra Therapeutics announced its clinical development strategy aimed at the resubmission of a New Drug Application (NDA) for its topical ocular 0.25% reproxalap. This investigational RASP modulator is poised for the treatment of dry eye disease, pending approval from the…
Study Finds New Paths in Zika Eye Condition Treatments
Researchers at Wayne State University School of Medicine have published a study in the journal iScience, shedding light on the potential treatment targets for eye abnormalities caused by the Zika virus (ZIKV) infection during pregnancy. The Role of Cholesterol Metabolism…
Regenxbio’s Gene Therapy for Wet AMD Found Successful
Regenxbio Inc. announced the publication of their phase 1/2a study results in The Lancet, showcasing the effectiveness of ABBV-RGX-314 as a one-time gene therapy for wet age-related macular degeneration (AMD). Lancet Study Highlights Safety and Efficacy of ABBV-RGX-314 The study,…